How should I taper off Lithium (carbonate / citrate) (lithium)?

Very slow taper recommended (months, not weeks). Abrupt discontinuation carries documented mania and suicide risk. Monitor mood and suicidality closely. Of all psychiatric medications, lithium has the most substantial post-discontinuation risk profile (mania, suicide, refractoriness). Plan very slow tapers with mood monitoring.

How long does Lithium (carbonate / citrate) withdrawal last?

Lithium (carbonate / citrate) withdrawal typically begins Days to weeks after stopping (mania risk peaks 2-12 weeks), peaks around 4-12 weeks, and resolves within Variable — many never re-establish mood stability after stopping long-term lithium. Lithium-discontinuation refractoriness: some patients lose response to lithium if restarted after stopping

Forums/Drug Profiles/

Lithium (carbonate / citrate) Tapering Guide

lithium

Mood StabilizerFDA 1970

Go to Community Forum

Overview

Lithium is the gold-standard mood stabilizer for bipolar disorder, with the strongest evidence for reducing suicide risk of any psychiatric medication. It has a narrow therapeutic window — therapeutic and toxic levels are close, requiring blood-level monitoring.

Common Doses

300mg capsules/tablets, 450mg ER, oral solution 300mg/5mL

Formulations

Capsules: 150mg, 300mg, 600mg; Tablets ER: 300mg, 450mg; Oral solution: 300mg/5mL (citrate)

Pregnancy

Category D

Mechanism of Action

Mechanism not fully understood. Inhibits inositol monophosphatase and glycogen synthase kinase-3 (GSK-3); modulates second-messenger systems. Effects on circadian rhythm and neuroprotection are likely contributors.

Taper Notes

Very slow taper recommended (months, not weeks). Abrupt discontinuation carries documented mania and suicide risk. Monitor mood and suicidality closely.

Hyperbolic Tapering Guidance

Of all psychiatric medications, lithium has the most substantial post-discontinuation risk profile (mania, suicide, refractoriness). Plan very slow tapers with mood monitoring.

Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.

Withdrawal Timeline

⏱Onset

Days to weeks after stopping (mania risk peaks 2-12 weeks)

📈Peak Severity

4-12 weeks

📉Resolution

Variable — many never re-establish mood stability after stopping long-term lithium

⚠️Protracted Risk

Lithium-discontinuation refractoriness: some patients lose response to lithium if restarted after stopping

Common Withdrawal Symptoms

rebound mania (significant — within weeks of stopping)anxietysleep disturbancerapid mood swingsincreased suicide risk especially with abrupt discontinuation

Interactions & Safety

Drug Interactions

NSAIDs, ACE inhibitors, ARBs, thiazide diuretics — increase lithium levels (toxicity risk)
Caffeine, theophylline — decrease lithium levels
Antipsychotics (especially haloperidol) — risk of neurotoxicity at therapeutic levels

Contraindications

Severe renal impairment
Severe cardiovascular disease
Pregnancy first trimester (Ebstein anomaly risk; benefit may still outweigh)

Toxicity

NARROW THERAPEUTIC INDEX. Toxicity at levels >1.5 mEq/L: tremor, ataxia, confusion, seizures, renal failure. Chronic use: hypothyroidism (~10-20%), nephrogenic diabetes insipidus, weight gain, fine tremor, cognitive blunting, long-term renal decline. Monitor TSH, creatinine, lithium level.

Pharmacokinetics

ADME Profile

Elimination

Renal — virtually entirely. Sodium/water status directly affects lithium levels.

Need a clinician who understands tapering?

Browse our map of deprescribing-informed providers worldwide.

Find a Deprescriber

Other Drug Profiles

Lexapro

escitalopram — SSRI

Zoloft

sertraline — SSRI

Paxil

paroxetine — SSRI

Prozac

fluoxetine — SSRI

Sources & References

Lithium (carbonate / citrate) (lithium) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.

Encyclopedic & chemical databases

Neutral, high-authority entity references.

Regulatory sources

Official prescribing information and safety notices.

FDA prescribing information — Lithium (carbonate / citrate) (lithium)

Peer-reviewed research

Primary literature cited in this taper guide.

Goodwin GM, Haddad PM, Ferrier IN, et al. 2016 — Discontinuation of mood stabilizers: practical considerations and review (Journal of Psychopharmacology)
Geddes JR, Burgess S, Hawton K, et al. 2004 — Discontinuation of lithium augmentation in elderly patients (American Journal of Psychiatry)
Horowitz MA, Taylor D 2019 — Tapering of SSRI treatment to mitigate withdrawal symptoms (hyperbolic taper) (The Lancet Psychiatry)

Clinical guidelines

Evidence-based deprescribing and prescribing standards.

Deprescribing-specific resources

Clinician-facing references on tapering protocols.

International Society for Bipolar Disorders (ISBD) — Specialty society guidance for bipolar maintenance pharmacotherapy
Deprescribing.org — Clinician-facing deprescribing algorithms

Patient-advocacy & lived-experience

Long-running communities documenting withdrawal experience.

Surviving Antidepressants — mood stabilizer tapering forum — Community archive of mood-stabilizer discontinuation experiences
Mad in America — mood stabilizer coverage — Independent journalism on lithium, lamotrigine, and valproate
Inner Compass Initiative — Withdrawal Project — Peer-led psychiatric drug withdrawal resources
RxISK — adverse drug reaction reporting — Independent database of mood-stabilizer adverse-effect reports

TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.